Compare EPSN & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPSN | HUMA |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | 184 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.2M | 155.4M |
| IPO Year | 2018 | N/A |
| Metric | EPSN | HUMA |
|---|---|---|
| Price | $6.00 | $0.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $6.19 |
| AVG Volume (30 Days) | 169.5K | ★ 4.1M |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.01% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $444.16 |
| Revenue Next Year | N/A | $248.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.20 | $0.55 |
| 52 Week High | $8.50 | $2.93 |
| Indicator | EPSN | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 65.91 |
| Support Level | $5.96 | $0.92 |
| Resistance Level | $6.50 | $1.27 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 55.77 | 98.11 |
Epsilon Energy Ltd is a North American on-shore focused independent natural gas and oil company engaged in the acquisition, development, gathering and production of natural gas and oil reserves. Its properties include Appalachian Basin-Pennsylvania, Permian Basin-Texas and New Mexico, Anadarko Basin-Oklahoma, Powder River Basin-Wyoming, Western Canadian Sedimentary Basin-Alberta, Canada. Its segments include The Upstream segment activities include acquisition, development and production of natural gas and oil reserves on properties within the United States and Canada; and The Gas Gathering segment partners with two other companies to operate a natural gas gathering system. The Upstream segment derives the majority of the revenue.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.